Mink Therapeutics Inc (INKT) Stock Price, Quote & News

Company Profile

MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab and balstilima...

Industry: Biotechnology

Sector: Healthcare

Phone: 212 994 8250

Website: minktherapeutics.com

Address:

149 Fifth Avenue, Suite 500, New York, United States

svertical1 Sep. 5 at 7:04 PM

$INKT It’s fairly normal to hear screams of ‘dilution’ on Stoktwits when following small Biotech, but just know…a legit ARDS drug is a $BILLION+ seller out the gate!

0 · Reply

svertical1 Sep. 5 at 3:58 PM

$INKT Regardless, a $59M market cap for a stock that could very soon have an approved treatment for ARDS is an insanely low valuation. Patient Trials for ARDS are quick, drug works or it doesn’t. Early results suggests T-797 + Anktiva works. https://investor.minktherapeutics.com/news-releases/news-release-details/mink-therapeutics-reports-new-data-agent-797-allo-inkt-cell/

0 · Reply

svertical1 Sep. 5 at 3:50 PM

$INKT I thought there was a combo Trial planned (for late this year) with ImmunityBio’s Anktiva in both Critically Ill Pneumonia with and without Sepsis, but I think ImmunityBio either was dropped or backed out. Appears both Companies are proceeding alone. Anyone know the back story?

0 · Reply

svertical1 Sep. 5 at 3:44 PM

$INKT A very different mode of action…so perhaps synergistic but not really a competitor. Fostamatinib - blocks the activity of the enzyme spleen tyrosine kinase (SYK). By blocking SYK's activity, fostamatinib reduces the immune system's destruction of platelets, so allowing the platelet count to rise, which reduces the likelihood of excessive bleeding

0 · Reply

OrientBeach Sep. 1 at 1:55 PM

$INKT We will soon have a new competitor in the quest for an ARDS therapeutic https://ctv.veeva.com/study/fostamatinib-for-treating-acute-respiratory-distress-syndrome-ards-in-hospitalized-adults Trail was schedule to start August 30, 2026

1 · Reply

svertical1 Aug. 31 at 9:40 PM

$INKT Great info….

0 · Reply

svertical1 Aug. 31 at 3:06 PM

$INKT Agree, but isn’t their plan to transition Phase 2 to Phase 3 based on positive P2 results?

1 · Reply

VintageCulture Aug. 29 at 4:40 AM

Watch NCRA 1000% runner potential, 0 shares to short 500% CTB $13 fair value MASSIVE MICRON TIES one of the most undervalued setups you will find $TROO $LCFY $INKT $ENLV 😏❤️❤️😏❤️

1 · Reply

Spartrap Aug. 28 at 1:49 PM

$INKT I'm switching this from the low conviction stack to the medium conviction stack. I like the patent that I found. Flimsy IP was my number #1 concern. I think they have a neat and quick shot on goal in the ARDS setting with reasonable POS. Nobody is seeing it yet so it's time to buy. GL.

2 · Reply

Spartrap Aug. 27 at 1:58 PM

$INKT this company might have a dusty two years old corporate deck, but it has this: NCT07615010 Don't sleep on it. It's hot AF

1 · Reply

MiNK Therapeutics Earnings Call Transcript: Q2 2026

Aug 13, 2026, 8:30 AM EDT - 23 days ago

MiNK Therapeutics Earnings release: Q2 2026

Aug 13, 2026, 8:30 AM EDT - 23 days ago

MiNK Therapeutics Quarterly report: Q2 2026

Aug 13, 2026, 7:30 AM EDT - 23 days ago

MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury

2026-08-06T16:05:52.000Z - 4 weeks ago

MiNK Therapeutics presents early observations from Phase 2 agenT-797 trial

Aug 6, 2026, 8:19 AM EDT - 4 weeks ago

MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates

Jun 17, 2026, 9:30 AM EDT - 2 months ago

MiNK Therapeutics Transcript: AGM 2026

Jun 3, 2026, 4:30 PM EDT - 3 months ago

MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting

2026-05-28T14:12:03.000Z - 3 months ago

MiNK Therapeutics doses first patient in agenT-797 trial

May 28, 2026, 9:04 AM EDT - 3 months ago

MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness

2026-05-20T15:15:48.000Z - 3 months ago

MiNK Therapeutics reports new data on agenT-797 at ATS 2026

May 20, 2026, 11:07 AM EDT - 3 months ago

MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications

May 15, 2026, 8:30 AM EDT - 3 months ago

MiNK Therapeutics Earnings Call Transcript: Q1 2026

May 15, 2026, 8:30 AM EDT - 3 months ago

MiNK Therapeutics Earnings release: Q1 2026

May 15, 2026, 8:30 AM EDT - 3 months ago

MiNK Therapeutics Quarterly report: Q1 2026

May 15, 2026, 7:30 AM EDT - 3 months ago

MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation

IBRX

2026-05-14T17:31:11.000Z - 3 months ago

MiNK Therapeutics initiates agenT-797 clinical trial

May 14, 2026, 7:30 AM EDT - 3 months ago

MiNK Therapeutics and First Lviv Territorial Medical Union Initiate Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness

May 12, 2026, 7:35 AM EDT - 3 months ago

MiNK Therapeutics Presents Clinical Evidence That a Single, Off-the-Shelf, iNKT Cell Product Drives Context-Dependent Immune Responses at ASGCT 2026

May 8, 2026, 4:30 PM EDT - 3 months ago

MiNK Therapeutics to Report First Quarter 2026 Financial Results and Highlight Platform Progress Across iNKT Cell Therapy Programs

Apr 30, 2026, 8:00 AM EDT - 4 months ago

MiNK Therapeutics Proxy statement: Proxy filing

2026-04-20T17:05:20.000Z - 4 months ago

MiNK Therapeutics management to meet virtually with B. Riley

$MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026$

Apr 3, 2026, 7:30 AM EDT - 5 months ago

MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026

Apr 1, 2026, 7:30 AM EDT - 5 months ago

MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference

Mar 31, 2026, 8:30 AM EDT - 5 months ago

MiNK Therapeutics Earnings Call Transcript: Q4 2025

Mar 31, 2026, 8:30 AM EDT - 5 months ago

MiNK Therapeutics Annual report: Q4 2025

Mar 31, 2026, 8:30 AM EDT - 5 months ago

MiNK Therapeutics Earnings release: Q4 2025

Mar 31, 2026, 7:30 AM EDT - 5 months ago

MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum

Mar 17, 2026, 7:30 AM EDT - 5 months ago

MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs

2026-03-11T14:11:00.000Z - 5 months ago

3 Penny Stocks to Watch Now, 3/11/26

ATPC LGVN

2026-03-10T12:33:59.000Z - 5 months ago

Why Is MiNK Therapeutics Stock (INKT) Up Today?

2026-03-10T09:40:45.000Z - 5 months ago

MiNK Therapeutics announces strategic collaboration with C-Further

Mar 10, 2026, 5:30 AM EDT - 5 months ago

MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers

2026-02-04T10:25:19.000Z - 7 months ago

MiNK Therapeutics announces new invariant natural killer T cells data

Feb 3, 2026, 9:30 PM EST - 7 months ago

MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia

2026-01-08T17:10:24.000Z - 8 months ago

MiNK, University of Wisconsin-Madison announce Phase 1 agenT-797 trial

Jan 8, 2026, 12:00 PM EST - 8 months ago

MiNK Therapeutics and University of Wisconsin–Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease

Dec 10, 2025, 7:00 AM EST - 8 months ago

MiNK Therapeutics Registration statement: Registration Filing

2025-11-20T16:45:18.000Z - 9 months ago

MiNK Therapeutics announces publication of new preclinical data for MiNK-215

Nov 20, 2025, 11:42 AM EST - 9 months ago

MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors

Nov 14, 2025, 8:30 AM EST - 9 months ago

MiNK Therapeutics Earnings Call Transcript: Q3 2025

Nov 14, 2025, 8:30 AM EST - 9 months ago

MiNK Therapeutics Quarterly report: Q3 2025

Nov 14, 2025, 8:30 AM EST - 9 months ago

MiNK Therapeutics Earnings release: Q3 2025

2025-11-14T12:35:56.000Z - 9 months ago

MiNK Therapeutics reports Q3 EPS (65c) vs (46c) last year

2025-11-07T22:00:18.000Z - 10 months ago

MiNK Therapeutics files $150M mixed securities shelf

2025-11-07T14:05:54.000Z - 10 months ago

MiNK Therapeutics reports updated clinical results on agenT-797

$MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025$

Nov 7, 2025, 9:00 AM EST - 10 months ago

MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025

Nov 7, 2025, 7:00 AM EST - 10 months ago

MiNK Therapeutics Registration statement: Registration Filing

2025-09-29T11:45:50.000Z - 11 months ago

MiNK Therapeutics appoints John Holcomb to board of directors

Sep 29, 2025, 7:30 AM EDT - 11 months ago

MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors

Sep 25, 2025, 7:30 AM EDT - 11 months ago

MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA

2025-09-18T11:40:33.000Z - 11 months ago

MiNK Therapeutics appoints Hammond as Head of Inflammatory, Pulmonary Diseases

Sep 18, 2025, 7:30 AM EDT - 11 months ago

MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development

2025-08-15T10:10:11.000Z - 1 year ago

MiNK Therapeutics upgraded to Buy from Neutral at H.C. Wainwright

Aug 14, 2025, 8:30 AM EDT - 1 year ago

MiNK Therapeutics Earnings Call Transcript: Q2 2025

Aug 14, 2025, 8:30 AM EDT - 1 year ago

MiNK Therapeutics Quarterly report: Q2 2025

Aug 14, 2025, 8:30 AM EDT - 1 year ago

MiNK Therapeutics Earnings release: Q2 2025

2025-08-14T11:40:29.000Z - 1 year ago

MiNK Therapeutics reports Q2 EPS ($1.06) vs (73c) last year

Aug 14, 2025, 7:30 AM EDT - 1 year ago

MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results

Jul 31, 2025, 8:30 AM EDT - 1 year ago

MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report

Jul 15, 2025, 8:21 AM EDT - 1 year ago

MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy

Jun 10, 2025, 1:33 PM EDT - 1 year ago

MiNK Therapeutics Announces Virtual Annual Shareholders Meeting

Jun 2, 2025, 9:29 AM EDT - 1 year ago

MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients

May 15, 2025, 8:30 AM EDT - 1 year ago

MiNK Therapeutics Earnings Call Transcript: Q1 2025

May 15, 2025, 8:30 AM EDT - 1 year ago

MiNK Therapeutics Quarterly report: Q1 2025

May 15, 2025, 8:30 AM EDT - 1 year ago

MiNK Therapeutics Earnings release: Q1 2025

May 15, 2025, 7:30 AM EDT - 1 year ago

MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress

Apr 30, 2025, 8:00 AM EDT - 1 year ago

MiNK Therapeutics Proxy statement: Proxy Filing

Apr 18, 2025, 8:00 AM EDT - 1 year ago

MiNK Therapeutics Proxy statement: Proxy Filing

Mar 18, 2025, 8:30 AM EDT - 1 year ago

MiNK Therapeutics Earnings Call Transcript: Q4 2024

Mar 18, 2025, 8:30 AM EDT - 1 year ago

MiNK Therapeutics Annual report: Q4 2024

Mar 18, 2025, 8:30 AM EDT - 1 year ago

MiNK Therapeutics Earnings release: Q4 2024

Mar 18, 2025, 7:30 AM EDT - 1 year ago

MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress

Mar 4, 2025, 7:30 AM EST - 1 year ago

MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

Feb 24, 2025, 8:30 AM EST - 1 year ago

MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting

Feb 12, 2025, 1:00 PM EST - 1 year ago

MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting

Jan 23, 2025, 2:13 PM EST - 1 year ago

MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI

Dec 20, 2024, 7:00 AM EST - 1 year ago

MiNK Therapeutics Proxy statement: Proxy Filing

Dec 18, 2024, 9:45 AM EST - 1 year ago

MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting

Dec 6, 2024, 7:00 AM EST - 1 year ago

MiNK Therapeutics Proxy statement: Proxy Filing

Nov 14, 2024, 8:30 AM EST - 1 year ago

MiNK Therapeutics Earnings Call Transcript: Q3 2024

Nov 14, 2024, 8:30 AM EST - 1 year ago

MiNK Therapeutics Quarterly report: Q3 2024

Nov 14, 2024, 8:30 AM EST - 1 year ago

MiNK Therapeutics Earnings release: Q3 2024

Nov 11, 2024, 7:30 AM EST - 1 year ago

MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report

Nov 7, 2024, 10:00 AM EST - 1 year ago

MiNK's iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024

Oct 31, 2024, 9:15 AM EDT - 1 year ago

MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors

Oct 8, 2024, 7:30 AM EDT - 1 year ago

MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors

Oct 4, 2024, 9:10 AM EDT - 1 year ago

MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024

Sep 9, 2024, 7:00 AM EDT - 1 year ago

MiNK Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 3, 2024, 7:30 AM EDT - 2 years ago

MiNK Therapeutics to Participate in H.C. Wainwright Global Investment Conference

Aug 13, 2024, 8:30 AM EDT - 2 years ago

MiNK Therapeutics Earnings Call Transcript: Q2 2024

Aug 13, 2024, 8:30 AM EDT - 2 years ago

MiNK Therapeutics Quarterly report: Q2 2024

Aug 13, 2024, 8:30 AM EDT - 2 years ago

MiNK Therapeutics Earnings release: Q2 2024

Aug 13, 2024, 8:00 AM EDT - 2 years ago

MiNK Therapeutics Registration statement: Registration Filing

Aug 13, 2024, 7:00 AM EDT - 2 years ago

MiNK Reports Second Quarter 2024 Results and Business Update

Aug 1, 2024, 7:30 AM EDT - 2 years ago

MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report

Jul 31, 2024, 7:30 AM EDT - 2 years ago

MiNK Therapeutics Regains Compliance with Nasdaq Capital Market Requirement

May 22, 2024, 7:30 AM EDT - 2 years ago

MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting

May 14, 2024, 8:30 AM EDT - 2 years ago

MiNK Therapeutics Earnings Call Transcript: Q1 2024

May 14, 2024, 8:30 AM EDT - 2 years ago

MiNK Therapeutics Quarterly report: Q1 2024

May 14, 2024, 8:30 AM EDT - 2 years ago

MiNK Therapeutics Earnings release: Q1 2024

May 14, 2024, 7:30 AM EDT - 2 years ago

MiNK Reports First Quarter 2024 Results

May 13, 2024, 7:30 AM EDT - 2 years ago

MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer

Apr 30, 2024, 7:30 AM EDT - 2 years ago

MiNK to Provide Corporate Update and First Quarter 2024 Financial Report

Apr 29, 2024, 8:00 AM EDT - 2 years ago

MiNK Therapeutics Proxy statement: Proxy Filing

Apr 8, 2024, 12:00 PM EDT - 2 years ago

MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR

Mar 21, 2024, 8:30 AM EDT - 2 years ago

MiNK Therapeutics Earnings Call Transcript: Q4 2023

Mar 21, 2024, 8:30 AM EDT - 2 years ago

MiNK Therapeutics Annual report: Q4 2023

Mar 21, 2024, 8:30 AM EDT - 2 years ago

MiNK Therapeutics Earnings release: Q4 2023

Mar 21, 2024, 7:00 AM EDT - 2 years ago

MiNK Reports Fourth Quarter and Year-End 2023 Results

Mar 7, 2024, 7:30 AM EST - 2 years ago

MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report

Mar 6, 2024, 8:30 AM EST - 2 years ago

MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024

svertical1 Sep. 5 at 7:04 PM

$INKT It’s fairly normal to hear screams of ‘dilution’ on Stoktwits when following small Biotech, but just know…a legit ARDS drug is a $BILLION+ seller out the gate!

0 · Reply

svertical1 Sep. 5 at 3:58 PM

0 · Reply

svertical1 Sep. 5 at 3:50 PM

0 · Reply

svertical1 Sep. 5 at 3:44 PM

0 · Reply

OrientBeach Sep. 1 at 1:55 PM

1 · Reply

svertical1 Aug. 31 at 9:40 PM

$INKT Great info….

0 · Reply

svertical1 Aug. 31 at 3:06 PM

$INKT Agree, but isn’t their plan to transition Phase 2 to Phase 3 based on positive P2 results?

1 · Reply

VintageCulture Aug. 29 at 4:40 AM

Watch NCRA 1000% runner potential, 0 shares to short 500% CTB $13 fair value MASSIVE MICRON TIES one of the most undervalued setups you will find $TROO $LCFY $INKT $ENLV 😏❤️❤️😏❤️

1 · Reply

Spartrap Aug. 28 at 1:49 PM

2 · Reply

Spartrap Aug. 27 at 1:58 PM

$INKT this company might have a dusty two years old corporate deck, but it has this: NCT07615010 Don't sleep on it. It's hot AF

1 · Reply

Spartrap Aug. 27 at 1:45 PM

$INKT with good P2 data in early 27, this could go to $105-125. I'd expect the SP to touch between a quarter and a third of that before results, depending on what transpires

0 · Reply

Spartrap Aug. 27 at 10:37 AM

$INKT I like this. The broadest claims won't hold, but the specific ones centered around ARDS + ECMO and methods to avoid CRS look solid enough, backed with the good P1 'unexpected' data. I don't think there's prior art for this

0 · Reply

Spartrap Aug. 21 at 11:44 PM

$INKT creeping up slowly but still vastly undervalued for a Phase 2 slash Phase 3 in ARDS company. The MC should be closer to 150 mil at this point

2 · Reply

Dancady1 Aug. 20 at 7:53 PM

$INKT …. Waiting

0 · Reply

OrientBeach Aug. 18 at 10:06 AM

$INKT Imstitutions added about 70.0k shares in Q2 https://fintel.io/so/us/inkt

0 · Reply

Dancady1 Aug. 14 at 6:02 PM

$INKT welp another goodish earning report for a company with no revenue, seems to be all good news referring to agent t797. Interesting how they started enrolling people in Brazil. Seems like very soon there will be a couple hundred guinea pigs for us hopefully they start trials on site in u.s. that would be a very positive sign. On a further note it is still a POS with no holders or volume

0 · Reply

enkemm Aug. 14 at 5:49 AM

$INKT Biotechguy....please, please, please kiss my entire rumpis roastis. That is from the Latin root Jalapeno.🤠

0 · Reply

Biotechguy21 Aug. 13 at 7:36 PM

$AGEN $INKT two pos stocks. only know how to atm SHs to death

0 · Reply

StocktwitsNews Aug. 13 at 4:58 PM

INKT Q2 2026 Earnings Summary $INKT https://stocktwits.com/news/earnings/ai summaries/inkt-q2-2026-earnings-summary/cZoq0swRJL0

0 · Reply

svertical1 Aug. 13 at 1:53 PM

$IBRX $INKT They came close to profiling a couple Patients, but very general info. Was hoping for a near Giuliani reference, but no luck. Still a mystery, given ‘Ladt Rites’ and then released days later.

0 · Reply

svertical1 Aug. 13 at 1:46 PM

$IBRX $INKT INKT to discuss seamless transition for Pneumonia Trial from Randomized P2 to P3. Preliminary results are encouraging. Not sure if she was referencing Agent 797 Trial or INKT + Anktiva Pneumonia Trial. Regardless, very encouraging in Critically Ill Pneumonia Trial. A TAM > Cancer!

0 · Reply

svertical1 Aug. 13 at 1:17 PM

$INKT I missed if any of these were US sites? If so, there is the mystery of Giuliani being given Last Rites and then quickly making miraculous recovery. So could it be 797 or Anktiva+797?

0 · Reply

Market Cap	57.31M
Revenue (ttm)	0.00
Net Income (ttm)	-12.49M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	5,800
Avg Vol	10,710
Day's Range	N/A - N/A
Shares Out	5.10M
Stochastic %K	84%
Beta	0.49
Analysts	Strong Sell
Price Target	$39.00